TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

17 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

16 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonEntire-body PET Scans for Multiple Sclerosis — Brain Health Alliance, Ladera RanchHome Based Infusions for Ocrelizumab — Amerita, CentennialProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiEffects of Ublituximab on Motor Functions in Multiple Sclerosis — Georgia State University, AtlantaClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenAssessment of Synaptic Density in MS — Brigham and Women's Hospital, BostonRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, Birmingham